Blog - Page 2 of 5673 - QualityStocks

MondayJun 29, 2026 10:30 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks

Cardio Diagnostics has positioned the science of epigenetics at the center of its diagnostic platform. Looking at an individual person’s epigenetics can provide invaluable insight into the impact of their lifestyle, behavior, and environment. Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution. When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It's an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests…

MondayJun 29, 2026 10:05 am

QualityStocksNewsBreaks – Swarmer, Inc. (NASDAQ: SWMR) Expands European Software Contract, Adds $1.02 Million in Expected Revenue

Swarmer (NASDAQ: SWMR) announced an amendment to its May 2026 software licensing agreement that increases the total contract value to $3.87 million and is expected to generate an additional $1.02 million in revenue. Under the revised agreement, Czech-based Progress TRW S.R.O. will purchase $1.41 million in SkyKnight software licenses, while Meta Bureau LLC increased its original autonomy software order from $1.38 million to $2.47 million. If all contract options are exercised by Meta Bureau and Progress TRW, the agreement could reach a total value of $14.20 million. The licenses cover Swarmer's software platform, including its operating system, artificial intelligence and…

MondayJun 29, 2026 9:45 am

SS Innovations International Inc. (NASDAQ: SSII) Reports Strong Q1 2026 Results with Surgical Robotics Expansion

SS Innovations reported record first-quarter 2026 revenue of $11.1 million, up 116.8% year over year, driven by growing adoption of its SSi Mantra surgical robotic system. The installed base reached 194 SSi Mantra systems across 11 countries, with nearly 9,750 cumulative robotic procedures completed. Regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines, expanded the company's international market access during the quarter. SS Innovations recently completed the world's longest-distance robotic cardiac telesurgery in history, demonstrating the capabilities of its remote surgery platform. The company continues pursuing regulatory clearance in both the United States and Europe while expanding its presence…

MondayJun 29, 2026 9:20 am

QualityStocksNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches AI Agent Platform for Patient Scheduling and Care Coordination

HealthLynked (OTCQB: HLYK) announced the launch of its next-generation AI Agent Platform, a conversational voice AI solution designed to automate patient scheduling, care coordination and healthcare communications for both patients and providers. The platform supports inbound and outbound voice interactions, enabling AI agents to schedule appointments, navigate physician office phone systems, collect patient and insurance information, perform intake functions, confirm appointments and provide 24/7 answering services for healthcare practices. The company said the platform is designed to help physician practices, accountable care organizations, health systems and insurers improve patient access while reducing administrative burdens and staffing requirements. HealthLynked plans a…

MondayJun 29, 2026 9:10 am

QualityStocksNewsBreaks – Xlife Sciences AG (SIX: XLS) Shareholders Approve All Annual Meeting Proposals

Xlife Sciences (SIX: XLS) announced that shareholders approved all proposals presented at the company's Annual General Meeting, where 3,134,367 voting shares, representing 54.3% of the total share capital, were represented. Chairman David L. Deck said the company strengthened its portfolio during the past year and highlighted the Nasdaq listing of portfolio company Veraxa Biotech (NASDAQ: VRXA) and the planned Landsteiner Scientific platform as key milestones supporting the next phase of growth. The company also emphasized the strategic importance of the planned Landsteiner Scientific platform, which is intended to accelerate the identification and development of novel therapeutic approaches while improving global…

MondayJun 29, 2026 9:00 am

QualityStocksNewsBreaks – Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N, WKN: A422EZ) Signs Agreement to Acquire Quantum.IQ

This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising. Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N, WKN: A422EZ) has entered into a definitive share purchase agreement to acquire Vancouver-based Quantum.IQ Technologies Inc., expanding its technology platform into quantum-resistant cybersecurity, cryptographic intelligence and enterprise security infrastructure modernization. The acquisition is expected to broaden Redwood's exposure beyond AI and operational intelligence into post-quantum cybersecurity, enterprise resilience and critical infrastructure modernization, subject to customary closing conditions and regulatory approvals. Under the agreement, Redwood will issue up to 14,033,558 common shares valued at approximately $2.98 per share,…

MondayJun 29, 2026 9:00 am

Why Market Street Capital Inc. Is ‘One to Watch’

Market Street Capital has evolved from its origins in investor relations into a diversified financial services platform spanning advisory, investment banking, capital raising, restructuring, valuation, and real estate services. The company focuses on established middle-market businesses with enterprise values ranging from $10 million to $1 billion, serving a defined client base that frequently requires sophisticated financial and strategic advisory services. Market Street Capital’s platform combines strategic advisory and transaction execution capabilities, allowing the firm to support clients across multiple stages of the corporate lifecycle. The leadership team brings experience across capital markets, structured finance, mergers and acquisitions, private credit, public…

FridayJun 26, 2026 3:01 pm

QualityStocksNewsBreaks – CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Focuses on Long-Term Opportunity as Market Dynamics Evolve

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising. CMX (CSE: CXC) (OTC: CXXMF) is an exploration-stage company advancing the wholly owned Clayton Silver Project in Idaho. The company was featured in a recent article that discussed its positioning to navigate increasing volatility in precious metals markets driven in part by the growing influence of derivatives trading. While derivatives can improve liquidity and provide hedging opportunities, they can also contribute to heightened leverage and skewed prices. Against this backdrop, the company remains focused on advancing its historic Clayton Silver Mine, which it believes could…

FridayJun 26, 2026 2:16 pm

QualityStocksNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Expands AI Voice Analytics Beyond Traditional Screening

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection. The company was featured in a recent article that discussed its efforts to broaden the scope of its platform with the development of a fatigue prediction model designed for high-risk workplace environments. “The fatigue detection capability is expected to become an additional feature within MindBio’s planned Edge AI Intoxication Detection Kiosks, which are being designed to identify signs of alcohol, drug impairment and fatigue from short voice…

FridayJun 26, 2026 12:00 pm

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease (‘CHD’) Detection

For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops. What makes CHD numbers particularly troubling is that so much of this is preventable. Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level. Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings…

Site Search

Company Search